SVB Securities analyst Daina Graybosch raised the firm’s price target on Innate Pharma (IPHA) to $10 from $9 and keeps an Outperform rating on the shares. SVB Securities is "pleased" by the partnership with Takeda (TAK) to develop ADCs for Celiac disease, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IPHA: